| Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group SF Barrington, NG Mikhaeel, L Kostakoglu, M Meignan, M Hutchings, ... Journal of clinical oncology 32 (27), 3048-3058, 2014 | 1727 | 2014 |
| Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ... Journal of clinical oncology 25 (5), 571-578, 2007 | 1700 | 2007 |
| Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer NH Bander, MI Milowsky, DM Nanus, L Kostakoglu, S Vallabhajosula, ... Journal of Clinical Oncology 23 (21), 4591-4601, 2005 | 627 | 2005 |
| Clinical role of FDG PET in evaluation of cancer patients L Kostakoglu, H Agress Jr, SJ Goldsmith Radiographics 23 (2), 315-340, 2003 | 527 | 2003 |
| PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease L Kostakoglu, M Coleman, JP Leonard, I Kuji, H Zoe, SJ Goldsmith Journal of Nuclear Medicine 43 (8), 1018-1027, 2002 | 486 | 2002 |
| Phase I trial of yttrium-90—labeled anti—prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer MI Milowsky, DM Nanus, L Kostakoglu, S Vallabhajosula, SJ Goldsmith, ... Journal of clinical oncology 22 (13), 2522-2531, 2004 | 374 | 2004 |
| International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ... Journal of Nuclear Medicine 54 (5), 683-690, 2013 | 350 | 2013 |
| Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen NH Bander, EJ Trabulsi, L Kostakoglu, D Yao, S Vallabhajosula, ... The Journal of urology 170 (5), 1717-1721, 2003 | 336 | 2003 |
| The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ... Haematologica 99 (6), 1107, 2014 | 298 | 2014 |
| Vascular targeted therapy with anti–prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors MI Milowsky, DM Nanus, L Kostakoglu, CE Sheehan, S Vallabhajosula, ... Journal of Clinical Oncology 25 (5), 540-547, 2007 | 283 | 2007 |
| 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma L Kostakoglu, SJ Goldsmith Journal of Nuclear Medicine 44 (2), 224-239, 2003 | 282 | 2003 |
| Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma L Kostakoglu, JP Leonard, I Kuji, M Coleman, S Vallabhajosula, ... Cancer 94 (4), 879-888, 2002 | 278 | 2002 |
| PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake L Kostakoglu, R Hardoff, R Mirtcheva, SJ Goldsmith Radiographics 24 (5), 1411-1431, 2004 | 268 | 2004 |
| Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma DA Pryma, BB Chin, RB Noto, JS Dillon, S Perkins, L Solnes, ... Journal of Nuclear Medicine 60 (5), 623-630, 2019 | 267 | 2019 |
| FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease L Kostakoglu, SJ Goldsmith, JP Leonard, P Christos, RR Furman, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2006 | 222 | 2006 |
| Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen NH Bander, DM Nanus, MI Milowsky, L Kostakoglu, S Vallabahajosula, ... Seminars in oncology 30 (5), 667-676, 2003 | 209 | 2003 |
| Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen DM Nanus, MI Milowsky, L Kostakoglu, PM Smith-Jones, ... The Journal of urology 170 (6), S84-S89, 2003 | 192 | 2003 |
| Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma JP Leonard, M Coleman, L Kostakoglu, A Chadburn, E Cesarman, ... Journal of Clinical Oncology 23 (24), 5696-5704, 2005 | 190 | 2005 |
| Pharmacokinetics and biodistribution of 111In-and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based … S Vallabhajosula, I Kuji, KA Hamacher, S Konishi, L Kostakoglu, ... Journal of Nuclear Medicine 46 (4), 634-641, 2005 | 182 | 2005 |
| Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? L Kostakoglu, SJ Goldsmith European journal of nuclear medicine 27, 1564-1578, 2000 | 178 | 2000 |
